GSA Capital Partners LLP purchased a new position in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 56,144 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,095,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Stevens Capital Management LP acquired a new position in AMAG Pharmaceuticals in the second quarter valued at about $273,000. Schwab Charles Investment Management Inc. lifted its position in shares of AMAG Pharmaceuticals by 9.3% during the second quarter. Schwab Charles Investment Management Inc. now owns 407,464 shares of the specialty pharmaceutical company’s stock worth $7,946,000 after purchasing an additional 34,833 shares in the last quarter. Russell Investments Group Ltd. lifted its position in shares of AMAG Pharmaceuticals by 13.7% during the second quarter. Russell Investments Group Ltd. now owns 1,170,332 shares of the specialty pharmaceutical company’s stock worth $22,878,000 after purchasing an additional 140,741 shares in the last quarter. Canada Pension Plan Investment Board lifted its position in shares of AMAG Pharmaceuticals by 15,100.0% during the second quarter. Canada Pension Plan Investment Board now owns 60,800 shares of the specialty pharmaceutical company’s stock worth $1,186,000 after purchasing an additional 60,400 shares in the last quarter. Finally, Robeco Institutional Asset Management B.V. lifted its position in shares of AMAG Pharmaceuticals by 25.0% during the second quarter. Robeco Institutional Asset Management B.V. now owns 975,748 shares of the specialty pharmaceutical company’s stock worth $19,026,000 after purchasing an additional 195,217 shares in the last quarter.

Shares of AMAG opened at $23.80 on Friday. The stock has a market cap of $839.41 million, a PE ratio of -4.17 and a beta of 0.48. AMAG Pharmaceuticals, Inc. has a 1 year low of $11.93 and a 1 year high of $26.10. The company has a debt-to-equity ratio of 0.99, a quick ratio of 1.95 and a current ratio of 2.06.

AMAG Pharmaceuticals (NASDAQ:AMAG) last issued its quarterly earnings results on Thursday, August 2nd. The specialty pharmaceutical company reported ($0.75) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.21) by ($0.54). AMAG Pharmaceuticals had a negative return on equity of 2.77% and a negative net margin of 36.87%. The business had revenue of $146.25 million for the quarter, compared to analyst estimates of $156.26 million. During the same period in the prior year, the company posted ($0.40) EPS. The firm’s revenue for the quarter was up 12.2% compared to the same quarter last year. analysts predict that AMAG Pharmaceuticals, Inc. will post -3.31 EPS for the current year.

In related news, CEO William K. Heiden sold 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 7th. The shares were sold at an average price of $25.00, for a total transaction of $125,000.00. Following the sale, the chief executive officer now directly owns 328,015 shares in the company, valued at $8,200,375. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 4.00% of the stock is currently owned by corporate insiders.

Several brokerages have recently issued reports on AMAG. BidaskClub raised shares of AMAG Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, August 14th. Cantor Fitzgerald reissued a “hold” rating and set a $18.00 price target (up previously from $17.00) on shares of AMAG Pharmaceuticals in a research report on Friday, August 3rd. Jefferies Financial Group reissued a “hold” rating and set a $22.00 price target on shares of AMAG Pharmaceuticals in a research report on Friday, August 3rd. Finally, ValuEngine raised shares of AMAG Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, June 6th. Seven research analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $22.85.

AMAG Pharmaceuticals Company Profile

AMAG Pharmaceuticals, Inc, a biopharmaceutical company, manufactures, develops, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds.

Featured Story: Market Capitalization, Large-Caps, Mid-Caps, Small-Caps

Want to see what other hedge funds are holding AMAG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG).

Institutional Ownership by Quarter for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.